Menu
Search
|

Menu

Close
X

Intec Pharma Ltd NTEC.OQ (NASDAQ Stock Exchange Capital Market)

5.60 USD
-0.03 (-0.44%)
As of Feb 21
chart
Previous Close 5.62
Open 5.60
Volume 9,937
3m Avg Volume 23,904
Today’s High 5.65
Today’s Low 5.50
52 Week High 9.80
52 Week Low 4.20
Shares Outstanding (mil) --
Market Capitalization (mil) --
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 2 analysts

KEY STATS

Revenue
No Data Available
FY
-
FY
-
FY
-
FY
-
EPS
No Data Available
FY
-
FY
-
FY
-
FY
-

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
35.64
Price to Sales (TTM)
vs sector
--
8.67
Price to Book (MRQ)
vs sector
--
5.21
Price to Cash Flow (TTM)
vs sector
--
26.03
Total Debt to Equity (MRQ)
vs sector
--
15.38
LT Debt to Equity (MRQ)
vs sector
--
12.01
Return on Investment (TTM)
vs sector
--
13.57
Return on Equity (TTM)
vs sector
--
15.19

EXECUTIVE LEADERSHIP

John Kozarich
Chairman of the Board, Since 2016
Salary: --
Bonus: --
Jeffrey Meckler
Chief Executive Officer, Vice Chairman of the Board, Since 2017
Salary: --
Bonus: --
Nir Sassi
Chief Financial Officer, Since 2016
Salary: --
Bonus: --
Nadav Navon
Chief Operating Officer, Since 2017
Salary: --
Bonus: --
Walt Linscott
Chief Administrative Officer, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

12 Hartom st. (RMPE building)
Har Hotzvim
P.O.Box 45219
JERUSALEM     91450

Phone: +9722.5864657

Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs. The Company is focusing on the clinical development program for the Phase III clinical study of the Accordion Pill Carbidopa Levodopa (AP-CDLD), for the treatment of advanced stages Parkinson’s disease patients. Its pipeline also comprises The Accordion Pill-Zaleplon, a drug for sleep onset, which is in Phase II clinical program. Furthermore under research is Accordion Pill-Undisclosed Drug for the prevention and treatment of small bowel non-steroidal anti-inflammatory drug (NSAID) induced ulcers.

SPONSORED STORIES